<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90887">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117453</url>
  </required_header>
  <id_info>
    <org_study_id>P120127</org_study_id>
    <secondary_id>2013-002531-15</secondary_id>
    <nct_id>NCT02117453</nct_id>
  </id_info>
  <brief_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</brief_title>
  <acronym>STATVAS</acronym>
  <official_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether rosuvastatin could reduce the subclinical
      markers of atherosclerosis and the incidence of major cardiovascular events in patients with
      primary necrotizing vasculitides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies demonstrated the presence of subclinical atherosclerosis in patients with
      ANCA-associated systemic necrotizing vasculitis. Since statins lower levels of inflammatory
      proteins and cholesterol, we hypothesized that people with ANCA-associated systemic
      necrotizing vasculitis but without indication for statin treatment according to
      recommandations might benefit from statin treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of change in mean carotid intima-media thickness for 12 predefined sites</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed with B-mode ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in endothelial function with brachial artery flow-mediated dilatation</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in serum biomarkers of subclinical atherosclerosis</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin, circulating endothelial, platelet and leucocytes microparticles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in vasculitis activity</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>BVAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vasculitis relapses</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>ANCA-associated Primary Necrotizing Vasculitides</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg/day</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient &gt; 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA),
        microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA,
        Churg-Strauss syndrome).

        Patients will fulfill the Chapel Hill Consensus Criteria and the American College of
        Rheumatology criteria, in remission of vasculitis.

        Patients in remission of vasculitis after induction therapy (for first flare or relapse),
        including corticosteroids associated or not with immunosuppressive agents according to
        Good Clinical Practice for the treatment of vasculitis, and at least 6 months after the
        beginning of induction therapy.

        Patients with informed and signed consent

        Exclusion Criteria:

        Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient
        with active vasculitis after induction therapy, requiring salvage therapy.

        Inability to sign informed consent. Inability to take the experimental treatment.
        Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV
        and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient
        requiring treatment with statin according to Afssaps recommandations published in 2005 as
        primary or secondary prevention.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Terrier, MD, PhD</last_name>
    <phone>+ 33 1 58 41 14 61</phone>
    <email>benjamin.terrier@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>+33 1 71 19 64 94</phone>
    <email>laurence.lecomte@nck.aphp.fr</email>
  </overall_contact_backup>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANCA vasculitis</keyword>
  <keyword>Statin</keyword>
  <keyword>Subclinical markers of atherosclerosis</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Arterial revascularization</keyword>
  <keyword>Unstable angina</keyword>
  <keyword>Death</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
